An observational study in Long COVID, COVID-19 Pandemic and Elderly Infection, sponsored by Peking University. Active, not recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Peking University · Observational
The Peking University Health Cohort in Anning, Yunnan (PKUHC-AN) is a prospective cohort study carried out in Anning, Yunnan. The primary aim of this study is to investigate the impact of COVID-19 on older adults' health, and to provide high-quality evidence of real world research for the optimization of prevention and control strategies of COVID-19 and other emerging infectious diseases. Data will be collected regarding health status, history of COVID-19 infections and vaccines, lifestyle and socioeconomic characteristics, as well as the short- and long-term health outcomes.
COVID-19 pandemic attributed to a great number of mortalities around the world in the last 3 years. About 46% of the global population are estimated to have been infected by the omicron variant and its sublineages. Health outcomes post COVID-19 has been of great concern globally since more and more people infected by SARS-CoV-2. Integrated efforts should be made to estimate the incidence of reinfections and long COVID in China, especially among older adults who are vunlerable and susceptible to COVID-19. In view of this, the Peking University Health Cohort Study in Anning, Yunnan aims to investigate the impact of COVID-19 on older adults' health, and to provide high-quality evidence of real world research for the optimization of prevention and control strategies of COVID-19 and other emerging infectious diseases. Data will be collected regarding health status, history of COVID-19 infections and vaccines, lifestyle and socioeconomic characteristics, as well as the short- and long-term health outcomes.
536 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 187 are open to participants now.
This study's enrollment of 11,527 is above the median of 160 across 149 observational studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Peking University is the lead sponsor of 418 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Older adults aged at least 60 years old living in Anning, Yunnan, China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group with history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
Other: no interventions
Group without history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
This is an observational study without any intervention.
Incidence of long COVID
The proportion of participants incurred any symptoms or diagnosed diseases of post-COVID in all infected participants.
Time frame: From baseline until the date of long COVID symptoms or date of death from any cause, whichever came first, assessed up to 12 months.
Reinfection incidence of COVID-19
The proportion of participants infected by COVID-19 at least 2 times. Measured by trained health professionals.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Cognitive impairment
Measured by health professionals using MMSE (Mini-Mental State Exam). The MMSE cognitive screening test is a 30-point questionnaire for analyzing several cognitive functions including memory, orientation, attention, calculation, and language. MMSE is measured on a scale between 0 and 30, where scores of 0-9, 10-20, 21-26, and 27-30 indicate severe, moderate, mild, and normal cognitive function, respectively.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Depression
Measured by health professionals using PHQ-9 (Patient Health Questionnaire-9). PHQ-9 provides a score ranging from 0 to 27, where scores of \<4, 5-9, 10-14, 15-19, and 20-27 represented no, mild, moderate, moderately severe, and severe depression, respectively.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Medical expenditure
Measured by health professionals using self-designed questionnaire about their past month outpatient expenditure and past year inpatient expenditure.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Incidence of catastrophic health expenditure
Measured by health professionals using self-designed questionnaire about their households' past year consumption expenditure (including food expenditure, cloths expenditure, transportation expenditure and so on), and calculated as the proportion of households whose out-of-pocket medical expenditure exceed 40% of household non-food expenditure.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Sleep quality
Measured by health professionals using PSQI (Pittsburgh Sleep Quality Index). PSQI reflects sleep for a month, includes 18 items (7 subscales): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. The range of PSQI global score is 0-21, and a score of \>5 or 7 is indicative of poor sleep quality.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Aug 2026, 39 months after the start.
Of 87 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 39 months is above that.
Counting every sponsor, half of 90 studies reached it within 25 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →